What's in Janssen Pharmaceutical K.K.'s pipeline?

Janssen Pharmaceutical K.K. has 22 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 6 in Phase 2, 9 in Phase 1.

Which companies overlap with Janssen Pharmaceutical K.K.'s portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Pfizer, Mylan Inc., Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Chong Kun Dang Pharmaceutical.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-pharmaceutical-k-k.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Janssen Pharmaceutical K.K. — Portfolio Competitive Intelligence Brief

Janssen Pharmaceutical K.K. pipeline: 0 marketed, 0 filed, 7 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 6 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
JNS020QD	JNS020QD	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
ITCZ Oral Solution	ITCZ Oral Solution	phase 3	Azole antifungal	Fungal CYP51 (lanosterol 14α-demethylase)	Infectious Disease
ITCZ-IV	ITCZ-IV	phase 3	Triazole antifungal	Fungal cytochrome P450 14α-demethylase (CYP51)	Infectious Disease
Placebo B (After CP)	Placebo B (After CP)	phase 3
JNS001	JNS001	phase 3			Immunology
CNTO 148	CNTO 148	phase 3	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)	Immunology
Placebo A (After CP)	Placebo A (After CP)	phase 3

Therapeutic area mix

Immunology · 3
Infectious Disease · 2
Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
Pfizer · 3 shared drug classes
Mylan Inc. · 2 shared drug classes
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · 2 shared drug classes
Chong Kun Dang Pharmaceutical · 2 shared drug classes
Medical University of Vienna · 2 shared drug classes
Bayer · 2 shared drug classes
Second Affiliated Hospital, School of Medicine, Zhejiang University · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Janssen Pharmaceutical K.K.:

Cite this brief

Drug Landscape (2026). Janssen Pharmaceutical K.K. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-pharmaceutical-k-k. Accessed 2026-05-16.